drugset / Trial / NCT03907800
Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of nab-paclitaxel combined with carboplatin for Chinese patients with triple-negative and HER2-positive breast cancer in the neoadjuvant setting.
Timeline
- Start
- 2019-04-01
- Primary completion
- 2022-10
- Completion
- 2022-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Nab-paclitaxel | Small molecule | 125 mg/m2 | Other |
| Background | Trastuzumab | Monoclonal antibody | — | — |